首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels
【24h】

Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels

机译:通过定量的血清免疫球蛋白M抗乙型肝炎核心抗体和乙型肝炎病毒DNA水平可以将乙型肝炎病毒相关的急性肝衰竭分为两种不同的亚型

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatitis B virus (HBV)-related acute liver failure (HBV-ALF) may occur after acute HBV infection (AHBV-ALF) or during an exacerbation of chronic HBV infection (CHBV-ALF). Clinical differentiation of the two is often difficult if a previous history of HBV is not available. Quantitative measurements of immunoglobulin M (IgM) anti-hepatitis B core antibody (anti-HBc) titers and of HBV viral loads (VLs) might allow the separation of AHBV-ALF from CHBV-ALF. Of 1,602 patients with ALF, 60 met clinical criteria for AHBV-ALF and 27 for CHBV-ALF. Sera were available on 47 and 23 patients, respectively. A quantitative immunoassay was used to determine IgM anti-HBc levels, and real-time polymerase chain reaction (rtPCR) was used to determine HBV VLs. AHBV-ALFs had much higher IgM anti-HBc titers than CHBV-ALFs (signal-to-noise [S/N] ratio median: 88.5; range, 0-1,120 versus 1.3, 0-750; P < 0.001); a cut point for a S/N ratio of 5.0 correctly identified 44 of 46 (96%) AHBV-ALFs and 16 of 23 (70%) CHBV-ALFs; the area under the receiver operator characteristic curve was 0.86 (P < 0.001). AHBV-ALF median admission VL was 3.9 (0-8.1) log10 IU/mL versus 5.2 (2.0-8.7) log10 IU/mL for CHBV-ALF (P < 0.025). Twenty percent (12 of 60) of the AHBV-ALF group had no hepatitis B surface antigen (HBsAg) detectable on admission to study, wheras no CHBV-ALF patients experienced HBsAg clearance. Rates of transplant-free survival were 33% (20 of 60) for AHBV-ALF versus 11% (3 of 27) for CHBV-ALF (P = 0.030). Conclusions: AHBV-ALF and CHBV-ALF differ markedly in IgM anti-HBc titers, in HBV VLs, and in prognosis, suggesting that the two forms are, indeed, different entities that might each have a unique pathogenesis. (HEPATOLOGY 2011)
机译:乙型肝炎病毒(HBV)相关的急性肝衰竭(HBV-ALF)可能在急性HBV感染(AHBV-ALF)或慢性HBV感染加重期间(CHBV-ALF)发生。如果以前没有HBV病史,则通常很难对两者进行临床区分。免疫球蛋白M(IgM)抗乙型肝炎核心抗体(抗HBc)滴度和HBV病毒载量(VLs)的定量测​​量可能使AHBV-ALF与CHBV-ALF分离。在1,602例ALF患者中,有60例符合AHBV-ALF的临床标准,而27例符合CHBV-ALF的标准。分别有47名和23名患者可获得血清。定量免疫测定法用于确定IgM抗HBc水平,实时聚合酶链反应(rtPCR)用于确定HBV VLs。 AHBV-ALFs的IgM抗HBc滴度比CHBV-ALFs高得多(信噪比[S / N]中位数:88.5;范围:0-1120与1.3,0-750; P <0.001);正确确定信噪比为5.0的切入点,可以确定46个(96%)AHBV-ALF中的44个和23个(70%)CHBV-ALF中的16个;接收者操作者特征曲线下的面积为0.86(P <0.001)。 AHBV-ALF中位入院VL为3.9(0-8.1)log10 IU / mL,而CHBV-ALF为5.2(2.0-8.7)log10 IU / mL(P <0.025)。 AHBV-ALF组中有20%(60名患者中的12名)入院时没有检测到乙型肝炎表面抗原(HBsAg),而没有CHBV-ALF患者经历过HBsAg清除。 AHBV-ALF的无移植生存率是33%(60分之20),而CHBV-ALF的无移植生存率是11%(27分之3)(P = 0.030)。结论:AHBV-ALF和CHBV-ALF在IgM抗HBc滴度,HBV VLs和预后方面有显着差异,这表明这两种形式确实是不同的实体,可能各自具有独特的发病机理。 (2011年肝病)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号